Latest Peplin news

09-June-09

Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more

28-May-09

Peplin's Positive Phase II AK Trial Results Published in JAAD read more

17-May-09

Positive Results for Peplin's First Phase III AK Trial read more

15-May-09

Peplin Results for the Quarter Ended 31 March 2009 read more

›› More News

Welcome to Peplin

We are a Phase III specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. We are currently developing PEP005 (ingenol mebutate), or PEP005, which is a novel compound derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. Peplin has extensive international patent coverage over its technologies.

Company Highlights

$24m financing and Neosil acquisition complete

Phase III (REGION-I) Positive Results

Peplin announced positive results for PEP005 (ingenol mebutate) Gel in REGION-I, its Australian and US based Phase III actinic (solar) keratosis (AK) clinical trial for the treatment of lesions on non-head locations. REGION-I met its primary and secondary efficacy endpoints with statistically significant clearance of AK lesions vs. vehicle. PEP005 Gel is the first topical treatment to demonstrate a statistically significant benefit over vehicle across non-head anatomical locations, including back of hand with the median reduction in overall lesion count equal to 66.7%.

Phase IIb Positive Results

Peplin announced further results for PEP005 (ingenol mebutate) Gel in its positive Phase IIb actinic (solar) keratosis (AK) dose ranging clinical trial (PEP005-015) for the treatment of AK lesions on head locations. Peplin plans to advance a 0.015% concentration of PEP005 Gel applied once daily for three consecutive days to Phase III trials on head locations. For this dose and regimen, the trial results showed a median reduction in overall lesion count of 84.5% and a total clearance rate of 50.0%. Local skin responses to drug peaked at Day 4 and returned to pre-treatment levels by Day 15.

Funds to complete Phase III AK trials

Peplin announced a March 31, 2009 cash balance of US$26.1 million. Peplin believes this cash balance will be sufficient to fund Phase III testing of its lead product, PEP005 (ingenol mebutate) Gel for actinic (solar) keratosis.